Bringing together patients, caregivers, physicians, allied health professionals, and representatives from relevant national organizations, our research team identified and prioritized the top 10 unanswered questions related to the causes and management of pediatric inflammatory bowel disease (IBD).
This prospective study is part of the successful Horizon 2020 bid called PIBD-Safety Efficacy and Treatment Quality (PIBD-SET Quality). An online registry of rare and serious complications of paediatric inflammatory bowel disease (PIBD) has been established based on monthly E-cards sent to PIBD experts.
The purpose of this study is to develop and evaluate the TUMMY-CD index, a signs and symptoms index for pediatric Crohn's Disease scored directly from the patient without a proxy.
The objective of this risk-stratified randomized controlled trial in pediatric Crohn’s Disease (CD) is to compare effectiveness of weekly subcutaneously administered methotrexate (MTX) for maintaining relapse-free sustained steroid/enteric nutrition (EN) free 1 year remission with daily oral azathiopurine (AZA) in low risk pediatric CD patients and subcutaneously administered adalimumab in high risk pediatric CD patients.
The Crohn’s and Colitis Canada Genetic, Environmental, Microbial (GEM) Project is a global research study that looks to uncover possible triggers of Crohn’s disease.
This study is designed to assess whether bacteria in the gut are responsible for the relationship between previous diet and dietary therapy response. Learning about how diet affects IBD could lead to new, better treatments.
This study is being conducted to determine indirect and out of pocket costs incurred by caregivers, funders, and the health system in taking care of children with IBD. Additionally, the study will evaluate sociodemographic and disease characteristics associated with higher costs.
The “Direct Attributable Costs of Children with Inflammatory Bowel Disease in Canada: Predicting High-Costs Users of the Health System” study combines the CIDsCaNN inception cohort with health administrative data to determine predictors of high cost health system use. Examining attributable and overall direct health costs in children with IBD will set the stage for interventions that improve the quality and efficiency of care.
The Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE) Chronic Disease Network studies the interactions between the inflammation, miocrobiome, diet, and mental health in patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The Mind and Gut Interactions Cohort (MAGIC) studies the relationship between gut bacteria, diet, and GI symptoms of those suffering from IBS and IBD, compared to healthy people. This information will be used to develop new ways to treat these disorders and to understand how to best use our current treatments. We are also interested in understanding how stress and mental health, like depression and anxiety, can affect GI symptoms.